Literature DB >> 19096744

Factors predicting osteoporosis treatment initiation in a regionally based cohort.

A Cranney1, J F Tsang, W D Leslie.   

Abstract

UNLABELLED: Osteoporosis treatment initiation was assessed during the year after baseline BMD testing in 8,689 previously untreated women. Treatment initiation increased progressively as BMD T-scores decreased, but there was a gradient response rather than step increases at conventional T-score intervention thresholds.
INTRODUCTION: Bone mineral density (BMD) testing is used to identify those at high fracture risk and guide osteoporosis treatment (OTx) initiation. Clinical guidelines have used the World Health Organization T-score diagnostic cutoffs as thresholds for treatment intervention. Our objective was to assess whether OTx initiation tracks these T-score cutoffs.
METHODS: Eight thousand six hundred and eighty-nine women age > or = 50 years who had not been dispensed any OTx medication in the year prior to baseline BMD were identified from a regionally based database in the Province of Manitoba, Canada, and OTx initiation rates were analyzed.
RESULTS: Forty-four percent of women were dispensed OTx in the year after BMD. OTx initiation increased progressively as BMD T-scores decreased (8.2% normal, 41.0% osteopenic, 78.5% osteoporotic, p-for-trend < 0.0001). There was a gradient response to OTx initiation, rather than step increases at conventional T-score intervention thresholds. BMD was strongly associated with OTx (p < 0.0001) while age, weight, and fracture in the last year were not.
CONCLUSIONS: Physicians rely heavily on BMD T-score to decide on OTx initiation. Although guidelines suggest using clinical risk factors to guide decision making, we did not see evidence of this. More explicit methods of reporting fracture risk may help physicians select patients who are likely to derive the largest benefit from OTx.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19096744     DOI: 10.1007/s00198-008-0823-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  19 in total

1.  Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence.

Authors:  Neil Binkley; Gary M Kiebzak; E Michael Lewiecki; Diane Krueger; Ronald E Gangnon; Paul D Miller; John A Shepherd; Marc K Drezner
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

Review 2.  Assessment of fracture risk.

Authors:  John A Kanis; Frederik Borgstrom; Chris De Laet; Helena Johansson; Olof Johnell; Bengt Jonsson; Anders Oden; Niklas Zethraeus; Bruce Pfleger; Nikolai Khaltaev
Journal:  Osteoporos Int       Date:  2004-12-23       Impact factor: 4.507

3.  Absolute fracture risk reporting in clinical practice: a physician-centered survey.

Authors:  W D Leslie
Journal:  Osteoporos Int       Date:  2008-02-01       Impact factor: 4.507

Review 4.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

5.  An assessment tool for predicting fracture risk in postmenopausal women.

Authors:  D M Black; M Steinbuch; L Palermo; P Dargent-Molina; R Lindsay; M S Hoseyni; O Johnell
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

6.  Contribution of clinical risk factors to bone density-based absolute fracture risk assessment in postmenopausal women.

Authors:  W D Leslie; C Metge; L Ward
Journal:  Osteoporos Int       Date:  2003-04-25       Impact factor: 4.507

7.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

8.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.

Authors:  John A Kanis; Olof Johnell; Dennis M Black; Robert W Downs; Somnath Sarkar; Thomas Fuerst; Roberta J Secrest; Imre Pavo
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

9.  BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.

Authors:  Katie L Stone; Dana G Seeley; Li-Yung Lui; Jane A Cauley; Kristine Ensrud; Warren S Browner; Michael C Nevitt; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2003-11       Impact factor: 6.741

10.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors:  D Marshall; O Johnell; H Wedel
Journal:  BMJ       Date:  1996-05-18
View more
  7 in total

1.  Validation of a case definition for osteoporosis disease surveillance.

Authors:  W D Leslie; L M Lix; M S Yogendran
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  Hip fracture and other predictors of anti-osteoporosis drug use in Norway.

Authors:  H M Devold; A J Søgaard; A Tverdal; J A Falch; K Furu; H E Meyer
Journal:  Osteoporos Int       Date:  2012-07-10       Impact factor: 4.507

3.  The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trial.

Authors:  L Bessette; K S Davison; S Jean; S Roy; L G Ste-Marie; J P Brown
Journal:  Osteoporos Int       Date:  2011-02-11       Impact factor: 4.507

4.  Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women.

Authors:  J Yu; I Goldshtein; V Shalev; G Chodick; S Ish-Shalom; O Sharon; A Modi
Journal:  Int J Clin Pract       Date:  2015-08-17       Impact factor: 2.503

5.  Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA.

Authors:  C Asche; R Nelson; C McAdam-Marx; M Jhaveri; X Ye
Journal:  Osteoporos Int       Date:  2009-10-02       Impact factor: 4.507

6.  Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.

Authors:  Zeren Ma; Yong Li; Ming Zhou; Kedi Huang; Hejun Hu; Xiaoping Liu; Xiaosheng Xu
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

7.  Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.

Authors:  Ethel S Siris; Jingbo Yu; Katalin Bognar; Mitch DeKoven; Anshu Shrestha; John A Romley; Ankita Modi
Journal:  Clin Interv Aging       Date:  2015-11-05       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.